Premium
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology
Author(s) -
Suzuki Maya,
Curran Kevin J.,
Cheung NaiKong V.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25513
Subject(s) - chimeric antigen receptor , medicine , antigen , antibody , immunology , immunotherapy , bispecific antibody , immune system , receptor , cancer research , monoclonal antibody
Cancer immunotherapy using antigen‐specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging. Pediatr Blood Cancer 2015;62:1326–1336. © 2015 Wiley Periodicals, Inc.